Executive Summary

Global Transcatheter Pulmonary Valve Replacement (TPVR) Market was valued at USD 287.6 million in the year 2019. Increasing penetration with innovation of TPVR technology which allows easier implantation and better outcome coupled with rapidly mounting population with cardiovascular diseases with increase in demand for less invasive procedures, including companies making major investments in expanding their product portfolio and geographical presence, has been anticipated to infuse growth in the market for Transcatheter Pulmonary Valve Replacement (TPVR) during the forecast period of 2020-2025. An oligopolistic structure, the TPVR market is characterized by the presence of only three products that are FDA approved with many products at the clinical stage.

Pulmonary Regurgitation is anticipated to witness the largest market share owing to growing adoption of less invasive procedures and preferring TPVR over SAVR procedure supported by key players providing these procedures to the patients at low cost. Companies constantly engaged in offering a wide range of products in order to provide increased life expectancy will be accelerating the Transcatheter Pulmonary Valve Replacement (TPVR) market growth in the coming years.

Hospitals and Ambulatory Surgical Centers attained substantial market share under End User segment, chiefly on the back of increasing investment in research and development with reviving economic growth and surging valvular diseases. Among the regions, Europe, followed by North America and APAC, will experience remarkable market share owing to escalating growth in demand for less invasive procedures which will prove to be more effective for the patients with heart diseases clubbed with presence of positive economic growth and increasing incidence of Pulmonary Stenosis and Pulmonary Regurgitation backed with growing presence of leading key players and burgeoning demand for effective and less invasive products in countries including Italy, France among others will be propelling the Transcatheter Pulmonary Valve Replacement (TPVR) market growth during the period of 2020-2025.

Scope of the Report

• The report analyses Transcatheter Pulmonary Valve Replacement (TPVR) market By Value.
• The report analyses Transcatheter Pulmonary Valve Replacement (TPVR) Market By Application Type (Pulmonary Stenosis, Pulmonary Regurgitation, Others).
• The report assesses the Transcatheter Pulmonary Valve Replacement (TPVR) market By End User (Hospitals, Ambulatory Surgical Centers, Others).
• The Global Transcatheter Pulmonary Valve Replacement (TPVR) Market has been analysed By Region (North America, Europe, Asia Pacific) and By Country (United States, Germany, China).
• The key insights of the report have been presented through the frameworks of Major mergers and acquisitions. Also, the attractiveness of the market has been presented By Region, Product Type and End User. Additionally, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Venus Medtech, Abbott, Medtronic, Boston Scientific, Edwards Life sciences.
• The report presents the analysis of Transcatheter Pulmonary Valve Replacement (TPVR) market for the historical period of 2015-2019 and the forecast period of 2020-2025.

Key Target Audience

• Pharmaceutical Companies
• Start-ups
• Investment Banks
• Consulting and Advisory Firms
• Venture capitalists